Bio-Techne's Ella Platform Receives CE-IVD Marking in EU

Bio-Techne (NASDAQ: TECH) announced its Ella automated immunoassay platform has received CE-IVD marking in the European Union, enabling commercial sales across the region. The Ella system provides high-sensitivity immunoassays for clinical diagnostics, with results in minutes. This regulatory approval expands the platform's market reach and supports Bio-Techne's growth in the diagnostics segment.